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BACKGROUND: Transfusion-transmissible infectious agents such as human immunodeficiency virus 
(HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and Syphilis are among the greatest threats to 
blood safety for recipients. They are also the leading causes of death and chronic and life-threatening 
abnormalities.  
METHODS: A retrospective analysis of consecutive blood donors’ records covering the period between 
January 2010 and December 2014 was conducted to analyze for seroprevalence of HIV, HBV, HCV and 
syphilis among blood donors aged 17-65 years. The association of these infections with age group, blood 
group, their co-infection rate and year trends were analyzed. Linear regression analysis was used to 
determine trends of HIV, HBV, HCV and syphilis infections. Sterile venous anti-coagulated blood was 
collected from the donors and analyzed using highly sensitive and specific kits.    
RESULT: From the total of 6827 consecutive blood donors, 963(14.1%) had serological evidence of 
infection with at least one pathogen and 73(1.07%) had multiple infections. The overall seroprevalence 
of HIV, HBV, HCV and syphilis was 3.16%, 9.48%, 0.73% and 0.73% respectively. Among those with 
multiple infections, the most common combinations were HIV-HBV 41/73(56.2%). Blood group “O 
positive” was the most common with 51.62% followed by “A positive”. Moreover, significantly declining 
trends of HIV, HCV and syphilis seropositivity were observed over the study period. 
CONCLUSION: A substantial percentage of the blood donors harbour HIV, HBV, HCV and syphilis 
infections. Strict selection of blood donors and comprehensive screening of donors’ blood using standard 
methods are highly recommended to ensure the safety of blood for recipients. 
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INTRODUCTION   
 
Human immunodeficiency virus (HIV), hepatitis 
B virus (HBV) and hepatitis C virus (HCV) are of 
more important concern because of their 
prolonged presence in the blood and carrier or 
latent state. They are the leading causes of death 
and chronic and life-threatening abnormality. 
Blood transfusion accounts for 5-10% of HIV 
infections in sub-Saharan Africa (1). The United 
Nations Program on HIV/AIDS (UNAIDS) 
estimates that 24.5 million people are currently 
infected with HIV in sub-Saharan Africa, 
comprising more than 70% of the global HIV-
infected population (2). 
Based on a single point estimate, there are 
nearly 1.2 million people living with HIV/AIDS in 
Ethiopia.The prevalence rate in adults is estimated 
at 2.4% and the incidence rate is 0.29%. The 
prevalence and incidence rates significantly vary 
between geographical areas and with gender. The 
urban prevalence rate is estimated at 7.7%, while 
the rural prevalence rate is 0.9%. The prevalence 
rate is 1.7% for males and 2.6% for females. 
Among urban settings, the epidemic varies greatly 
from 2.4 in Somali region to 9.9% in Tigray,
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10.7% in Amhara and 10.8% in Afar regions. 
Rural HIV epidemic also varies significantly 
among regions with rural HIV prevalence ranging 
from 0.4% in Somali region to 1.5% in Amhara 
region (3). 
HIV transmission occurs through sexual 
contact, exposure to contaminated blood or blood 
products and perennially. HIV recognizes host 
cells by binding to the CD4 cell membrane 
receptor and multiplies within the host cell. HIV is 
one of the members of the human retrovirus and is 
associated with three presentations: asymptomatic 
infection, acute infection with symptoms, and 
acquired immune deficiency syndrome (AIDS). 
The last one is characterized by progressive 
immune deficiency accompanied by a wide range 
of opportunistic infections. HIV infection is 
detected by demonstrating HIV-specific antibodies 
with different test kit, and polymerase chain 
reaction detects the HIV genome in infected cells. 
Infection is prevented by screening blood products 
for HIV and education people to prevent 
transmission by sexual contact and sharing of 
needles (4). 
Hepatitis B virus (HBV) infection is a global 
health problem having 10 times great impact than 
AIDS. Worldwide, about 350 million people are 
chronic carriers of hepatitis B virus. Out of them, 
one-fourth is dying due to cancer or cirrhosis of 
liver (5, 6). In Indonesia (1981), 10% of the blood 
donors were positive for HBsAg (7). In Kinshasa 
and Democratic Republic of Congo, among 7,277 
blood donors, the incidences of HIV and HBsAg 
were 6.5% and 9.2% respectively (8). In Addis 
Ababa, in 1966, the mean prevalence of HBsAg 
among 1,260 households was 6.1% (9). The 
reported prevalence of carriers varies greatly from 
0.1% in the developed countries to 20% in some 
developing countries. There are no seasonal trend 
for HBV infection and high predilection for any 
age group. However, there are definite high-risk 
groups such as parenteral drug abusers, 
institutionalized persons, health care personnel, 
multiple transfused patients, organ transplant 
patients, hemodialysis patients and staff (10). The 
virus is highly infectious and relatively easy to be 
transmitted from one person to another by blood-
to-blood contact, during birth, via unprotected sex 
and by sharing needles(11).  
 
The WHO (1997) estimates that approximately 
3% of the world's population is to be infected 
with HCV and viremia persists in over 80%. In 
developing countries, the prevalence of 
antibodies to HCV is much higher, with reported 
rates reaching 4% to 6% in some parts of Africa 
and the Middle East (12). It is estimated the 
overall prevalence of HCV in Sub-Saharan Africa 
is 3.0%. The central African region has the highest 
estimated prevalence of 6%, West Africa with 
an estimated prevalence of 2.4%, and southern 
and east Africa with the lowest estimated 
prevalence of 1.6% (13). The prevalence of HCV 
infection varies throughout the world, the highest 
number of infection ranging from 6% to 28% in 
Egypt (14). The prevalence of antibody to HCV 
(anti-HCV) in healthy adult Ethiopian blood 
donors was 1.4% (15). Hepatitis C virus 
prevalence was 0.9% for the total population and 
1.3% for adults over 15 years of age in a study 
conducted on two blood banks in Addis Ababa. 
On the other hand, the prevalence of anti-HCV 
among Ethiopian patients with chronic hepatitis, 
cirrhosis of the liver and hepatocellular carcinoma 
(HCC) was found to be 21%, 36% and 46% in the 
study respectively (16). 
Syphilis is also a systemic disease caused by 
Treponema pallidum which can be spread by 
sexual contact, blood transfusion and via vertical 
transmission (17). In sub-Saharan Africa, syphilis 
remains a serious public health problem. The 
prevalence of active syphilis infection among 
African countries was 12.8% in Tanzania (18), 
and 3.8% in Kenya (19). A study conducted to 
assess the prevalence of infection with HIV, 
syphilis and HBV among Ethiopian blood donors 
in 1995 showed that the seroprevalence of HIV-1, 
syphilis and HBV was 16.7%, 12.8% and 14.4%, 
respectively (20). Information is very scarce on 
the sero-prevalence of HIV, HBV, HCV and 
syphilis among blood donors in Jigjiga city, 
Somali Regional State of Ethiopia. It should be 
noted that testing for HIV, HBV, HCV and 
syphilis infections is useful for epidemiological 
monitoring and public health planning. As a result 
of this dearth of information, guidelines and other 
adequate information on the preventive and 
control measures are essentially lacking in many 
settings in Ethiopia. Despite this, the aim of this 
study was to determine the seroprevalence of HIV, 
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HBV, HCV and syphilis in blood donors for 
epidemiological purpose and to prevent possible 
transmission of these infectious diseases in blood 
to the recipients or the health workers. 
 
SUBJECTS AND METHODS 
Study Area: This study was carried out in Jigjiga 
Blood Bank, Somali Regional State of Ethiopia on 
consecutive blood donors’ records covering the 
period between January 2010 and December 2014. 
This blood bank is the center where an effective 
blood banking system is catering  for all the blood 
needs of patients in the hospitals of this region. It 
is located 628Km east from the capital city, Addis 
Ababa. Institutional ethical clearance was obtained 
from the Research and Publication Committee of 
Jigjiga University. However, due to the nature of 
the study (retrospective review of blood donors’ 
records), informed consent was not obtained from 
the subjects of the study. 
Study Population: Since the study was 
retrospective, health data for 6827 blood donors 
who attended the blood donor’s bank of the region 
between January 2010 and December 2014 were 
collected. Verbal informed consent was obtained 
from the authorities of the blood bank and the 
protocol for this study was approved by the 
Ethical Committee of the Ethiopian Somali 
Regional Health Bureau. 
 
Collection and Processing of Samples: 
Blood samples were collected aseptically by veni-
puncture from the donors.The samples were 
analyzed for blood group, HIV-1 & 2, HBV, 
HCV, and Syphilis following standard procedures. 
Laboratory Diagnosis for HIV-1 and 2: Each 
donor’s serum sample was screened for HIV-1 and 
HIV-2 using Vironostika
®
 HIV Uni-Form II 
Ag/Ab. The detection of HIV-1 and HIV-2 in the 
blood was done following the manufacturer’s 
instructions(BioMerieux, Boxtel, The 
Netherlands). 
Laboratory Diagnosis for HBsAg and HCV 
Antibodies: Sera were checked for the presence 
of hepatitis B surface antigen (HBsAg) using 
ELISA, Hepanostika HBsAg(Murex Biotech Ltd, 
Dartford, UK). This is a fairly reliable test having 
more than 99.9% sensitivity and specificity. 
Similarly, IgG antibodies to HCV were detected 
using an ELISA technique (Murex anti-HCV 
version 4.0) according to the manufacturer’s 
instructions. 
Laboratory Diagnosis for Syphilis: Serum for all 
donors was tested for the presence of treponemal 
antibodies using rapid plasma regain test (RPR). 
The diagnosis was done following the 
manufacturer’s instructions (RPR, Wampole 
Laboratories, Princeton, N.J., USA). 
ABO Blood Grouping and Rhesus (RH) Typing: 
ABO and Rh blood groups determinations were 
carried out on a slide using monoclonal blood 
grouping antisera. The antisera; anti-A, anti-B, 
anti-AB, and anti-D were used following the 
manufacturer’s instructions(BIOTEC Laboratories 




Out of the 6827(6648 males and 179 females) 
individuals tested for HIV, HBV, HCV and 
Syphilis, 216(3.16%) were HIV positive, 
647(9.48%) were HBsAg positive, 50(0.73%) 
were HCV positive, while 50(0.73%) were 
syphilis positive (Table 1). The results showed 
that the majority of the subjects had blood group 
“O positive” with 51.62% followed by “A 
positive” (29.02%), “B positive” (14.25%) and 
“AB positive (3.05%) respectively. Age group and 
blood group wise distributions of HIV, HBsAg, 
HCV and syphilis positive cases are shown in 
Tables 2 and 3. 
Table 1: Gender related prevalence of HIV, HBV, HCV and Syphilis among blood donors at Jigjiga blood 
bank, Eastern Ethiopia 2010-2014.  
 
 












Male  6648(97.38) 211(3.09) 638(9.35) 49(0.72) 48(0.70) 
Female  179(2.62) 5(0.07) 9(0.13) 1(0.02) 2(0.03) 
  6827(100.00) 216(3.16) 647(9.48) 50(0.73) 50(0.73) 





Table 2: Blood group wise distribution of HIV, HBV, HCV and Syphilis positive cases among blood donors 
at Jigjiga blood bank, Eastern Ethiopia 2010-2014. 
 
 










O   positive  162(4.59) 463( 13.14 ) 36( 1.02) 28(0.79) 3524(51.62) 
A   positive  30(1.51) 112(5.65) 7( 0.35) 13(0.66) 1981(29.02) 
B    positive  18(1.85) 53(5.45) 7(0.72) 5(0.51) 973(14.25) 
AB  positive  2(0.96) 9(4.33) 0( 0.00) 1(0.48) 208(3.05) 
O    negative 1(1.15) 7(8.05) 0(0.00 ) 2(2.29) 87(1.27) 
A    negative 2(5.88) 2(5.88) 0( 0.00) 0(0.00) 34(0.49) 
B    negative 1(5.88) 1(5.88) 0( 0.00) 1(5.88) 17(0.25) 
AB   negative 0(0.00) 0(0.00) 0(0.00) 0(0.00) 3(0.04) 
  216(3.16) 647(9.48) 50(0.73) 50(0.73) 6827(100.00) 
  
 
Table 3: Age group wise distribution of HIV, HBV, HCV and Syphilis positive cases among blood donors 
at Jigjiga blood bank, Eastern Ethiopia 2010-2014. 
 
 










17-25 35(1.36) 244(9.47) 15(0.58) 6(0.23) 2578(37.76) 
26-35 101(3.42) 259(8.77) 22(0.75) 23(0.78) 2952(43.24) 
36-45 60(5.57) 111(10.29) 11(1.02) 17(1.58) 1078(15.79) 
46-55 20(9.22) 33(15.21) 2(0.92) 4(1.84) 217(3.18) 
56-65 0(0.00) 0(0.00) 0(0.00) 0(0.00) 2(0.03) 
 216(3.16) 647(9.48) 50(0.732) 50(0.732) 6827(100.00) 
 
Of all donated blood during the study period, 
963(14.1%) had serological evidence of infection 
with at least one pathogen and 73(1.07%) had 
multiple infections. Among those with multiple 
infections, the most common combinations were 
HIV-HBV 41/73(56.2%) and HIV-HCV 
11/73(15.1%) (Table 4). 
 
Table 4: prevalence of co-infections of HIV, 
HBV, HCV and syphilis among blood donors at 
Jigjiga blood bank, Eastern Ethiopia 2010-2014. 
 
Co-infections Number Percent 
HIV-Syphilis 7 9.6 
HIV-HBV 41 56.2 
HIV-HCV 11 15.1 
HBV-Syphilis 10 13.7 
HBV-HCV 2 2.7 
HCV-Syphilis 2 2.7 
Total 73 100.0 
Significantly declining trends of HIV, HBV, HCV 
and syphilis (p<0.001) seroprevalence were 
observed over the five years study period. The 
seroprevalence of HIV was 6.4% in 2010 and 
showed decreased prevalence for consecutive 
years afterwards, and a highly significant decrease 
was observed in the year 2014. The 
seroprevalence of HBV decreased from 18.2% in 
2010 to 9.6% in 2011 and increased again to 
11.1% in 2012 and 10.6% in 2013. HCV 
prevalence decreased significantly from 2.1% in 
2010 to 0.0% in 2011, 0.9% in 2012, 0.3% in 2013 
and 0.8% in 2014. Similarly, the prevalence of 
syphilis decreased progressively from 2.4% in 
2010 to 0.4% in 2011 and 2012, 0.7% in 2013 and 
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Table 5: Trends of seroprevalence of HIV, HBV, HCV and syphilis among blood donors at Jigjiga blood 
bank, Eastern Ethiopia 2010-2014. 
 
 












2010 676 43(6.4) 123(18.2) 14(2.1) 16(2.4) 
2011 736 36(4.9) 71(9.6) 0(0.0) 3(0.4) 
2012 1167 40(3.4) 129(11.1) 10(0.9) 5(0.4) 
2013 1496 58(3.9) 158(10.6) 4(0.3) 10(0.7) 
2014 2752 39(1.4) 166(6.0) 22(0.8) 16(0.6) 
Total 6827 216(3.2) 647(9.5) 50(0.7) 50(0.7) 
       p-value of  LR  for trend           - 0.000 0.000 0.000 0.000 




It is a well-known fact that HIV, HBV and HCV 
are global infectious pathogens contributing to 
mortality and morbidity in all ages (21). In this 
study, a total of 216(3.16%) out of the 6827 
subjects screened were seropositive for HIV, 
647(9.48%) were positive for HBV, while 
50(0.732%) and 50(0.732%) were positive for 
HCV and syphilis respectively.  
The diseases studied are fairly age-specific 
and behavior-dependent. People of ages 20-40 
years have been found to be more sexually and 
economically the most active group and HIV is at 
high prevalence in those groups (21). In our study, 
HIV prevalence has been found highest in the age 
group of 46-55 compared to the the age group of 
26-35 which contradicts earlier reports (21, 22). 
This variation in prevalence between two groups 
may be attributed to the variation in duration and 
opportunity for risk exposure, the continuous 
sharing of sharps and use of unsterilized materials 
such as barbing clippers. The fact that these 
subjects are proposing donors does not exclude 
them from being potential sources or carriers of 
transfusion transmissible infections (TTI’s), 
especially HIV. Thus, this study has uncovered the 
fact that donors themselves are not an exemption 
to the general HIV pandemic ravaging sub-
Saharan Africa in general and Ethiopia precisely. 
In this study, the prevalence of HIV was 3.16% 
which is in line with the earlier reports (22). 
However, it is less than the report, 47.54%, in 
Nigeria (23). This variation may be due to the 
small sample size they used. 
The seroprevalence of HBV (9.48%) in our study 
is lower than the previous reports of 10.4% in 
Nigeria (12), 15.0% in Ghana (24) and 14.4 % in 
Ghana (20) and 6.2% in Ethiopia (25); but it is 
higher than the earlier report in Ethiopia with 
4.7% (22). Our finding is in agreement with the 
report of 9.2% in Kinshasa (8).  Most countries in 
Africa, including Ethiopia, have high endemicity 
for hepatitis B. This clearly explains the reason 
behind the high seroprevalence obtained in our 
study. 
The prevalence of hepatitis C (0.7%) 
identified in this study is less than the reports by 
Jesse et al. (26) with the age group 20-29 more 
infected and the reports of 5.71% in Nigeria (23). 
However, it is slightly similar with the prevalence 
of antibody to HCV in healthy adult Ethiopian 
blood donors of 1.4% (15) and 1.7%(25). 
Nevertheless, the prevalence of HIV, HBV and 
HCV could be higher in commercial sex workers, 
their clients and intravenous drug users, since they 
are involved in high risk behaviors. 
Prevalence of active syphilis infection among 
African countries was 12.8% in Tanzania (18), 
and 3.8% in Kenya (19). However, the prevalence 
of syphilis (0.7%) in this study is less than that of 
the above reports; but in agreement with the 
earlier reports in Ethiopia (22). A study conducted 
to assess the prevalence of infection with HIV, 
syphilis and HBV among Ethiopian blood donors 
in 1995 showed that the seroprevalences of HIV-1, 
syphilis and HBV were 16.7%, 12.8% and 14.4%, 
respectively (20). A major limitation of our study 
is the fact that our sample size was small. A study 
done on 6827 subjects alone cannot provide 
overall prevalence of HIV, HBsAg, HCV and 





syphilis status in the country as a whole. Yet, it 
can reflect the disease status in the larger 
Ethiopian community. 
In this study, significantly declining trends of 
HIV, HBV, HCV and syphilis seroprevalences 
were observed among blood donors over the study 
period. This finding is consistent with the 
observed declining trends of HIV, HCV and 
syphilis in the report at Gondar University 
Hospital, Ethiopia (22), and with the observed 
declining trends of HIV seroprevalence in the 
general population of Ethiopia (27), as well as the 
declining trends of HIV and syphilis infection 
among pregnant women in Addis Ababa (28). The 
subsequent declining in HIV seroprevalence may 
be due to the effect of the prevention programs 
that have been instituted in recent years (29). 
The HIV-HBV co-infection rate of 41/73 
(56.2%) and the 11/73 (15%) HIV-HCV co-
infection observed in this study are higher than the 
report from Gondar University Hospital, Ethiopia 
(22), in Port Harcourt (30), in Cameroon (31), and 
higher than the 40% HIV/HBV co-infection rate 
reported by Lodenyo et al. (32). This high rate of 
co-infection and the statistically significant 
relationship between HIV and syphilis, HIV and 
HCV infections might be due to the fact that these 
pathogens share common modes of transmission 
and risk groups (33, 34). 
Also, because this study was a retrospective 
analysis, we could not gather information about 
the socio-economic status and behavioral patterns 
which are major indices in measuring the 
prevalence of these infections. The seroprevalence 
data, behavioral patterns and socio-economic 
status of our community indicates that there is a 
high potential for the spread of HBsAg, and HIV 
in Jigjiga city of Ethiopian Somali Regional State. 
If adequate preventive measures are not put in 
place, these infections can lead to the death of the 
most productive ages of the general population 
thereby resulting in a vicious cycle of poverty and 
vulnerability. 
In coclusion, the high prevalence of HBV, 
HIV, HCV and syphilis observed among the blood 
donors in the study area calls for extensive blood 
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